Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -18.00p -20.93% 68.00p 457,702 16:27:39
Bid Price Offer Price High Price Low Price Open Price
68.20p 72.00p 84.20p 67.20p 84.20p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.02 -3.78 -2.30 90.0

Silence Therapeutics (SLN) Latest News (4)

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
10/12/201816:49Silence Therapeutics (the old SR Pharma)47,667
06/10/201608:04Gower Productions Presents ....."PREDICTA BID"52
05/10/201619:29port-
29/5/201309:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-12-10 16:35:0368.00495336.60UT
2018-12-10 16:27:1770.007,1585,010.60O
2018-12-10 16:25:1071.68214153.40O
2018-12-10 16:01:0270.0020,00014,000.00O
2018-12-10 15:53:0268.827,5005,161.50O
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

DateSubject
10/12/2018
08:20
Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 86p.
Silence Ther. has a 4 week average price of 67.20p and a 12 week average price of 67.20p.
The 1 year high share price is 206p while the 1 year low share price is currently 67.20p.
There are currently 132,322,452 shares in issue and the average daily traded volume is 133,774 shares. The market capitalisation of Silence Ther. is £89,979,267.36.
20/11/2018
08:36
callumross: Well, there is certainly plenty newsflow expected in the next 6 weeks to drive the share price up (or down!). To recap, Quark phase 3 results, High Court case against Alnylam commencing and application for phase 1 trial.
05/10/2018
16:37
1gw: Interesting to compare the shares on loan position with the share price chart. According to Euroclear, SoL monthly average this year is as follows: 1.4m Jan (average shares on loan) 1.4m Feb 2.6m Mar 4.3m Apr 4.2m May 4.2m Jun 4.1m Jul 3.9m Aug 2.3m Sep So it looks like a significant increase in short positions in March and April (assuming the SoL correlates to short positions) may have helped to knock the shareprice off its 200p perch. hTtps://my.euroclear.com/apps/en/monthly-stock-loan-data.html#month=eq:9&year=eq:2018&limit=0&search=1&order=asc:abbreviation
03/8/2018
13:10
tshirley12: Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
06/3/2018
08:32
1gw: I missed the Nasdaq reference at first glance. Interesting. I get the impression this is a management team with more than half an eye focused on the share price and the potential to support the price with the carefully managed release of information.
04/12/2017
08:30
1gw: Nice bit of profit-taking on the arwr stake. I wonder what that will do to the arwr share price today? And whether it's all part of the game to get some meaningful dialogue going with arwr?
28/9/2017
07:23
rogen83: Arrowhead stake now worth £20m or 30p of SLNs share price Good work Ali
07/9/2017
13:36
1gw: It has at least put the brakes on the share price. Who knows - if there's any truth to the suggestions that Alnylam might look to settle the patent dispute by taking over Silence then now might be a good time to strike. Certainly it seemed to me from the Alnylam call that Alnylam see the Fitusiran death as tragic but by no means an end to their hopes for the drug.
24/8/2017
14:24
1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions...
21/8/2017
15:19
1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.
04/5/2017
15:00
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181211 04:08:44